Michael Narachi is President at Orexigen Therapeutics, Inc. (OREX). They have made 3 open-market trades across 3 companies since 2012, most recently 2026-05-14.
CIK 0001380022
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
3 open-market purchases totalling $766K since 2012, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| OREX | BUY | 2014-09-15 | 2014-09-15 | $4.78 | $239K | N/A | N/A | N/A |
| CLDN | BUY | 2014-02-04 | 2014-02-06 | $8.00 | $500K | N/A | N/A | N/A |
| OREX | SELL · 10b5-1 | 2012-07-17 | 2012-07-19 | $7.66 | $1.1M | N/A | N/A | N/A |
| OREX | SELL · 10b5-1 | 2012-07-12 | 2012-07-13 | $6.70 | $1.0M | N/A | N/A | N/A |
| OREX | SELL · 10b5-1 | 2012-06-28 | 2012-06-29 | $5.89 | $1.3M | N/A | N/A | N/A |
| AMAG | BUY | 2012-05-24 | 2012-05-29 | $13.55 | $27K | -23.6% | -3.6% | -3.6% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.